Efficacy of thalidomide-or lenalidomide-based therapy in proliferative multiple myeloma

P. Kapoor; S. Kumar; S. J. Mandrekar; K. M. Laumann; A. Dispenzieri; M. Q. Lacy; D. Dingli; M. A. Gertz; R. A. Kyle; P. R. Greipp; S. V. Rajkumar; T. E. Witzig

doi:10.1038/leu.2011.54

Efficacy of thalidomide-or lenalidomide-based therapy in proliferative multiple myeloma

P. Kapoor, S. Kumar, S. J. Mandrekar, K. M. Laumann, A. Dispenzieri, M. Q. Lacy, D. Dingli, M. A. Gertz, R. A. Kyle, P. R. Greipp, S. V. Rajkumar, T. E. Witzig

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	1195-1197
Number of pages	3
Journal	Leukemia
Volume	25
Issue number	7
DOIs	https://doi.org/10.1038/leu.2011.54
State	Published - Jul 2011

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2011.54

Cite this

Efficacy of thalidomide-or lenalidomide-based therapy in proliferative multiple myeloma. / Kapoor, P.; Kumar, S.; Mandrekar, S. J.; Laumann, K. M.; Dispenzieri, A.; Lacy, M. Q.; Dingli, D.; Gertz, M. A.; Kyle, R. A.; Greipp, P. R.; Rajkumar, S. V.; Witzig, T. E.

In: Leukemia, Vol. 25, No. 7, 07.2011, p. 1195-1197.

Research output: Contribution to journal › Article › peer-review

@article{60b00ae323634d8c9cb34686b1b9a629,

title = "Efficacy of thalidomide-or lenalidomide-based therapy in proliferative multiple myeloma",

author = "P. Kapoor and S. Kumar and Mandrekar, {S. J.} and Laumann, {K. M.} and A. Dispenzieri and Lacy, {M. Q.} and D. Dingli and Gertz, {M. A.} and Kyle, {R. A.} and Greipp, {P. R.} and Rajkumar, {S. V.} and Witzig, {T. E.}",

note = "Funding Information: Shaji Kumar receives research support for clinical trials from Celgene, Novartis, Millennium, Bayer, Genzyme, Merck and Cephalon. Angela Dispenzieri and Martha Q Lacy receive research funding from Celgene. Philip R. Greipp receives research funding grants from Celgene and Novartis, and is on the advisory board of Amgen. Morie A Gertz receives research support from Millennium and Novartis, and honorarium from Celgene and Millennium. Robert A Kyle has been on the disease and/or data monitoring committees of Celgene, Novartis, Merck, Bristol-Myers Squibb Keryx Biopharmaceuticals, Onyx Pharmaceuticals and Johnson and Johnson sponsored studies. He is also a consultant for Millennium and receives honoraria from Binding Site. Thomas E Witzig receives research support from Celgene and Novartis. He has participated in Celgene advisory boards of Celgene, but has deferred the honorarium to Mayo Clinic, Rochester, MN, USA. The remaining authors declare no conflict of interest. Funding Information: This study is supported in part by the grants CA 62242, CA 107476 and CA 62242 from the National Cancer Institute, National Institutes of Health, Bethesda, MD and the Eastern Cooperative Oncology Group, Boston, MA (SVR).",

year = "2011",

month = jul,

doi = "10.1038/leu.2011.54",

language = "English (US)",

volume = "25",

pages = "1195--1197",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Efficacy of thalidomide-or lenalidomide-based therapy in proliferative multiple myeloma

AU - Kapoor, P.

AU - Kumar, S.

AU - Mandrekar, S. J.

AU - Laumann, K. M.

AU - Dispenzieri, A.

AU - Lacy, M. Q.

AU - Dingli, D.

AU - Gertz, M. A.

AU - Kyle, R. A.

AU - Greipp, P. R.

AU - Rajkumar, S. V.

AU - Witzig, T. E.

N1 - Funding Information: Shaji Kumar receives research support for clinical trials from Celgene, Novartis, Millennium, Bayer, Genzyme, Merck and Cephalon. Angela Dispenzieri and Martha Q Lacy receive research funding from Celgene. Philip R. Greipp receives research funding grants from Celgene and Novartis, and is on the advisory board of Amgen. Morie A Gertz receives research support from Millennium and Novartis, and honorarium from Celgene and Millennium. Robert A Kyle has been on the disease and/or data monitoring committees of Celgene, Novartis, Merck, Bristol-Myers Squibb Keryx Biopharmaceuticals, Onyx Pharmaceuticals and Johnson and Johnson sponsored studies. He is also a consultant for Millennium and receives honoraria from Binding Site. Thomas E Witzig receives research support from Celgene and Novartis. He has participated in Celgene advisory boards of Celgene, but has deferred the honorarium to Mayo Clinic, Rochester, MN, USA. The remaining authors declare no conflict of interest. Funding Information: This study is supported in part by the grants CA 62242, CA 107476 and CA 62242 from the National Cancer Institute, National Institutes of Health, Bethesda, MD and the Eastern Cooperative Oncology Group, Boston, MA (SVR).

PY - 2011/7

Y1 - 2011/7

UR - http://www.scopus.com/inward/record.url?scp=79960226207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960226207&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.54

DO - 10.1038/leu.2011.54

M3 - Article

C2 - 21468037

AN - SCOPUS:79960226207

VL - 25

SP - 1195

EP - 1197

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -

Efficacy of thalidomide-or lenalidomide-based therapy in proliferative multiple myeloma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this